State of New Jersey Common Pension Fund D Sells 1,124 Shares of Avantor, Inc. (NYSE:AVTR)

State of New Jersey Common Pension Fund D cut its holdings in shares of Avantor, Inc. (NYSE:AVTR) by 0.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 246,334 shares of the company’s stock after selling 1,124 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Avantor were worth $5,190,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in AVTR. Creative Planning increased its position in shares of Avantor by 54.0% during the third quarter. Creative Planning now owns 28,136 shares of the company’s stock worth $728,000 after acquiring an additional 9,866 shares in the last quarter. Blue Trust Inc. boosted its holdings in Avantor by 414.5% during the third quarter. Blue Trust Inc. now owns 7,547 shares of the company’s stock worth $195,000 after purchasing an additional 6,080 shares during the last quarter. Sequoia Financial Advisors LLC purchased a new position in Avantor during the third quarter worth about $255,000. Tandem Capital Management Corp ADV boosted its holdings in Avantor by 6.7% during the third quarter. Tandem Capital Management Corp ADV now owns 49,582 shares of the company’s stock worth $1,268,000 after purchasing an additional 3,130 shares during the last quarter. Finally, Louisiana State Employees Retirement System purchased a new position in Avantor during the third quarter worth about $4,874,000. 95.08% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

AVTR has been the topic of several analyst reports. Morgan Stanley cut their price target on shares of Avantor from $27.00 to $25.00 and set an “overweight” rating on the stock in a report on Monday, February 10th. UBS Group restated a “neutral” rating and set a $25.00 price target (down from $29.00) on shares of Avantor in a report on Friday, January 17th. Raymond James restated an “outperform” rating and set a $24.00 price target (down from $26.00) on shares of Avantor in a report on Monday, February 10th. Stifel Nicolaus cut their price target on shares of Avantor from $28.00 to $26.00 and set a “buy” rating on the stock in a report on Monday, February 10th. Finally, Robert W. Baird cut their price target on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a report on Monday, October 28th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $25.92.

Avantor Stock Performance

Avantor stock opened at $17.73 on Thursday. The firm’s 50 day simple moving average is $21.16 and its 200 day simple moving average is $23.05. The company has a current ratio of 1.07, a quick ratio of 0.70 and a debt-to-equity ratio of 0.54. The firm has a market capitalization of $12.07 billion, a PE ratio of 17.05, a price-to-earnings-growth ratio of 1.60 and a beta of 1.28. Avantor, Inc. has a 1-year low of $17.14 and a 1-year high of $28.00.

Avantor (NYSE:AVTR) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.26 by $0.01. Avantor had a net margin of 10.49% and a return on equity of 12.17%. During the same period last year, the business posted $0.22 EPS. As a group, analysts expect that Avantor, Inc. will post 1.06 earnings per share for the current fiscal year.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.